

HOLOGIC



Bayer

Same suite. **More Modalities.**

Hologic and Bayer are coming together to provide a coordinated solution to offer breast imaging options that can optimize your workflow and help improve the patient experience.

Together, we can help streamline installation, coordinate training, and provide comprehensive service offerings that allow for seamless delivery and support.



HOLOGIC




Working together to create a brighter future.

Hologic + Bayer are partnering to provide a coordinated contrast-enhanced mammography solution. Enhance patient care by providing cost-effective contrast-enhanced exams in a comfortable environment.^{1,2}



How Contrast-Enhanced Mammography Uses Functional Imaging to Find Cancers

A standard CEM acquisition requires two exposures per view: one at high-energy and the other at low energy. The recombined image appears as a subtracted image highlighting iodine accumulation, while eliminating the surrounding breast tissue.¹² This allows you to detect increased formations of blood vessels associated with tumor development and provides images of tumor angiogenesis. Only the low kV and subtraction images are archived.



The Benefits of Contrast-Enhanced Mammography

Expanded diagnostic solutions

- **Clinically comparable** – CEM and breast MRI both have high sensitivity in the visualization of lesions.^{1,6}
- **Treat more patients** – May use CEM when breast MRI is contraindicated.³
- **Reduce costs** – CEM is typically 25% of the cost of breast MRI.¹⁰



Optimize workflow

- **Exam room** – CEM exams typically require 30-minute room blocking vs. 30-60 minutes for bMRI.¹⁰ Allows utilization of the MRI suite for other exams.
- **Scheduling** – CEM exams generally do not need pre-authorization.**
- **Read time** – CEM images are quick and efficient to read, with a shorter mean interpretation time compared to breast MRI.¹⁰

Create a comfortable patient experience

- **Familiar exam** – same room and equipment as the mammogram.
- **Focus on patient safety** – with automated power injection system set-up features and quick visual indicators.
- **A faster exam** – 8-10 minutes¹⁰ for CEM vs. 45 min⁹ for breast MRI
- **More comfortable positioning** – avoids uncomfortable prone position and anxiety associated with the noisy and enclosed MRI tube.³



Versatility with the **Affirm® Breast Biopsy Guidance System**

Biopsy Hard to **Detect Lesions**

Lesions identified with I-View 2.0 CEM software can be found and correlated with Affirm® Contrast Biopsy technology, for precise tissue biopsy.

To begin a Contrast-Enhanced Biopsy exam, patients are injected with iodinated contrast agent† to enhance the visualization of suspicious lesions.⁵ Lesions are then localized using a scout view and the 15-degree image pairs taken approximately 2 minutes after completion of the injection.¹²



Flexible solution

- Perform contrast biopsy in either a seated or decubitus position using the Akrus chair.
- Efficient and easy to learn with a simple user interface.¹¹

Streamline workflow

- Quick setup and 13-minute average procedure time for 2D and 3D™ biopsy.¹¹
- Virtually eliminate the need for manual calculations. Preprogrammed for Hologic's Eviva®, ATEC® and Brevera® biopsy needles.
- Contrast-enhanced biopsy exams utilize familiar stereotactic biopsy workflow using contrast-enhanced images for targeting.

Exceptional imaging^{11,‡}

- Same exceptional image quality as original diagnostic image.
- Perform the contrast biopsy using the same mammographic equipment as the initial CEM exam.

How to make Contrast-Enhanced Mammography a reality in your facility



Procedure requirements

- 3Dimensions™ or Selenia® Dimensions® mammography system with minimum SW levels (1.10/2.1 for CEM, 1.12/2.3 for CEBx).
- I-View® 2.0 CEM technology (includes both a software license and a copper filter).
- Affirm® Contrast Biopsy license and an Affirm Upright biopsy system on the same system as I-View CEM technology.
- Power injection system, like the MEDRAD® Stellant FLEX CT Injection System with Certegra® Workstation

Additional equipment

- Akrus™ Mammography Positioning Chair.

Important Safety Information

- Patients can have adverse reactions to contrast agents.
- For contrast agents used with these devices, please see Full Prescribing Information for further details including Important Safety Information.

*Not sold by Hologic

**No pre-authorization needs identified.

†Compared to 2D stereotactic biopsy

References

1. Cozzi A, Magni V, Zanardo M, et al. Contrast-enhanced Mammography: A Systematic Review and Meta-Analysis of Diagnostic Performance. *Radiology*. 2022 Mar;302(3):568-581. **2.** Jochelson M, Dershaw D, Sung J, et al. Bilateral contrast-enhanced dual-energy digital mammography: feasibility and comparison with conventional digital mammography and MR imaging in women with known breast carcinoma. *Radiology* 266(3) (2013) 743–751. **3.** Hobbess M, Taylor D, Buzynski S et al. "Contrast-enhanced spectral mammography (CESM) and contrast enhanced MRI (CEMRI): Patient preference and tolerance" *J Med Imaging Radiat Oncol*. 2015 Jun;59(3):300-5. [Epub 2015 Apr 21]. **4.** Savaridas SL, Whelehan P, Warwick VR, et al. *Br J Radiol*. Contrast-enhanced digital breast tomosynthesis and breast MRI to monitor response to neoadjuvant chemotherapy: patient tolerance and preference. 2022 Jun 1;95(1134):20210779 **5.** The Principles of Contrast Mammography. Andrew Smith, Ph.D. (WP-00084 Rev02 2021) **6.** Xian W, Rao H, Zhou L. A meta-analysis of contrast enhanced spectral mammography versus MRI in the diagnosis of breast cancer. *Thorac Cancer*. 2020 Jun;11(6):1423-1432. **7.** Bernardi D, Vatteroni G, Acquaviva A, et al. Contrast-Enhanced Mammography Versus MRI in the Evaluation of Neoadjuvant Therapy Response in Patients With Breast Cancer: A Prospective Study. *AJR Am J Roentgenol*. 2022 Sep 14:1-11. **8.** Montrognon F, Clatot F, Berghian A, et al. Impact of preoperative staging with contrast-enhanced mammography for localized breast cancer management. *Br J Radiol*. 2022 Jun 1;95(1134):20210765. **9.** <https://www.radiologyinfo.org/en/info.cfm?pg=breastmr> **10.** Patel B, Gray R, Pockaj B. Potential Cost Savings of Contrast-Enhanced Digital Mammography. *AJR* 2017;208:W231-W237. **11.** Schrading S, Martine D, Dirrichs T, et al. "Digital Breast Tomosynthesis-guided Vacuum-assisted Breast Biopsy: Initial Experiences and Comparison with Prone Stereotactic Vacuum-assisted Biopsy." *Radiology*. 2015 274:3, 654-662 E-pub 2014 Nov 12. **12.** MED-00525 Rev.001 (3/21)

www.hologic.com | info@hologic.com | 1.800.442.9892

**Hologic Headquarters
United States / Latin America**
250 Campus Drive
Marlborough, MA 01752
USA Tel: +1.508.263.2900
Sales: +1.781.999.7453
Fax: +1.781.280.0668
Email: info@hologic.com

FDA clearance: K123873 and K202294

PB-01036 Rev 002 (4/24) © 2024 Hologic Inc. All rights reserved. Hologic, 3D, 3D Mammography, Affirm, ATEC, Brevera, Dimensions, Eviva, I-View, Selenia, The Science of Sure and associated logos are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries. Bayer, the Bayer Cross, MEDRAD, MEDRAD Stellant FLEX, and Stellant FLEX are trademarks owned by and/or registered to Bayer in the U.S. and/or other countries. This information is intended for medical professionals in the U.S. and other markets and is not intended as a product solicitation or promotion where such activities are prohibited. Because Hologic materials are distributed through websites, eBroadcasts and tradeshows, it is not always possible to control where such materials appear. For specific information on what products are available for sale in a particular country, please contact your local Hologic representative. This is a general information tool for medical professionals and is not a complete representation of the product(s)' Instruction for Use (IFU) or Package Insert, and it is the medical professionals' responsibility to read and follow the IFU or Package Insert. The information provided may suggest a particular technique or protocol however it is the sole responsibility of the medical professional to determine which technique or protocol is appropriate. At all times, clinicians remain responsible for utilizing sound patient evaluation and selection practices, and for complying with applicable local, state, and federal rules and regulations regarding accreditation, anesthesia, reimbursement, and all other aspects of in-office procedures. In no event shall Hologic be liable for damages of any kind resulting from your use of the information presented. The individuals depicted in this brochure are actors and not actual health care providers or patients.